Alere Determine®: A new look for early infectious disease detection, Alere re-launches Determine point-of-care tests with new brand image
Morges, Switzerland, 7 April 2011 – Alere has re-launched its Determine® portfolio of products for the accurate and rapid diagnosis of infectious diseases, including the HIV 1/2 Ag/Ab Combo test, to fit within its new brand image. Over the past year, the company (formerly called Inverness Medical) has rebranded many of its key products and services to the new Alere brand to ensure immediate recognition of their high quality and generate confidence in the results they deliver.
Determine quickly and accurately detects the antibodies or antigens that indicate infection from HIV/AIDS, hepatitis B, and syphilis at the point of care, producing results in just 15 to 20 minutes. After purchasing the Determine portfolio from Abbott in 2005, Alere has developed these products further to ensure excellent diagnostic performance anywhere in the world. The Determine® HIV- 1/2 Ag/Ab Combo is just one example of this performance excellence: a fourth-generation rapid diagnostic test, it detects HIV infection 5-7 days earlier than HIV antibody-only tests1.
“The accurate and rapid diagnosis of infectious diseases is a major global public health priority, especially in the developing world. Since the emergence of HIV/AIDS, it has become even more critical to diagnose early, not only to save lives, but also to prevent the spread of life-threatening infections. The Determine products are at the forefront of this movement and will continue to deliver the same benefit of early diagnosis, but with a new, fresh look,” said Tom Lindsay, Business Development Manager – Africa, Alere Healthcare.
The simple two-step Determine tests require no power or water for use, and they can be run with minimal training, as just a fingerstick of blood is needed for sample collection. They can also be easily stored and transported, which is one of the primary reasons why the Determine name is widely used and recognised globally.
All Determine products have been renamed as follows:
* Determine® HIV- 1/2 Ag/Ab Combo is now Alere Determine® HIV- 1/2 Ag/Ab Combo
* Determine® HIV- 1/2 is now Alere Determine® HIV- 1/2
* Determine® HBsAg is now Alere Determine® HBsAg
* Determine® Syphilis TP is now Alere Determine® Syphilis TP
“Alere believes in bringing healthcare closer to the patient and with our new brand image we aim to make it clear to healthcare professionals that we hold many of the quality tools they need to make more informed healthcare choices,” explained Tom Lindsay.
By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home. Alere’s global leading products and services, as well as its new product development efforts, focus on cardiology, women’s health, infectious disease, oncology and toxicology. Alere is headquartered in Waltham, Massachusetts.
For more information regarding Alere please visit www.alere.com